SG11202008864VA - Intracellular delivery of biomolecules to modify immune response - Google Patents

Intracellular delivery of biomolecules to modify immune response

Info

Publication number
SG11202008864VA
SG11202008864VA SG11202008864VA SG11202008864VA SG11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA
Authority
SG
Singapore
Prior art keywords
biomolecules
immune response
intracellular delivery
modify immune
modify
Prior art date
Application number
SG11202008864VA
Inventor
Scott Loughhead
Leeann Talarico
Alfonso Vicente-Suarez
Matt Booty
Howard Bernstein
Katarina Blagovic
Armon R Sharei
Kelan Hlavaty
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Publication of SG11202008864VA publication Critical patent/SG11202008864VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11202008864VA 2018-03-12 2019-03-11 Intracellular delivery of biomolecules to modify immune response SG11202008864VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862641987P 2018-03-12 2018-03-12
US201862738941P 2018-09-28 2018-09-28
US201962794516P 2019-01-18 2019-01-18
PCT/US2019/021705 WO2019178006A2 (en) 2018-03-12 2019-03-11 Intracellular delivery of biomolecules to modify immune response

Publications (1)

Publication Number Publication Date
SG11202008864VA true SG11202008864VA (en) 2020-10-29

Family

ID=66102189

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008864VA SG11202008864VA (en) 2018-03-12 2019-03-11 Intracellular delivery of biomolecules to modify immune response

Country Status (16)

Country Link
EP (1) EP3765068A2 (en)
JP (1) JP2021517813A (en)
KR (1) KR20200130835A (en)
CN (1) CN112135627A (en)
AU (1) AU2019234550A1 (en)
BR (1) BR112020018612A2 (en)
CA (1) CA3093828A1 (en)
CO (1) CO2020012584A2 (en)
CR (1) CR20200460A (en)
IL (1) IL277188A (en)
MA (1) MA52010A (en)
MX (1) MX2020009439A (en)
PH (1) PH12020551436A1 (en)
SG (1) SG11202008864VA (en)
TW (1) TW202003019A (en)
WO (1) WO2019178006A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
WO2020166729A1 (en) * 2019-02-14 2020-08-20 学校法人獨協学園獨協医科大学 T cell vaccine
KR20210134353A (en) 2019-02-28 2021-11-09 에스큐지 바이오테크놀로지스 컴퍼니 Delivery of Biomolecules to PBMCs to Modify the Immune Response
AU2020271040A1 (en) 2019-04-08 2021-11-18 Sqz Biotechnologies Company Cartridge for use in a system for delivery of a payload into a cell
CR20220576A (en) 2020-05-11 2022-12-07 Hoffmann La Roche Combination therapy with modified pbmcs and an immunoconjugate
KR20230058389A (en) 2020-07-29 2023-05-03 에스큐지 바이오테크놀로지스 컴퍼니 A method for stimulating an immune response against mutant RAS using nucleated cells
CN116322752A (en) 2020-07-29 2023-06-23 Sqz生物技术公司 Methods of stimulating immune responses to mutant RAS using anuclear cells
EP4271407A1 (en) 2020-12-29 2023-11-08 SQZ Biotechnologies Company Formulations of activating antigen carriers
CA3203706A1 (en) 2020-12-29 2022-07-07 Howard Bernstein Formulations for cryopreservation of pbmcs
US20220233677A1 (en) 2020-12-29 2022-07-28 Sqz Biotechnologies Company Methods for treating cancers with modified pbmcs
WO2022147443A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Methods for treating cancers with activating antigen carriers
CN115252772A (en) * 2021-04-30 2022-11-01 华普生物技术(江苏)股份有限公司 Application of artificially synthesized deoxyoligonucleotide containing CpG single strand in vaccine
WO2023010090A1 (en) 2021-07-29 2023-02-02 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
EP4430168A1 (en) 2021-11-11 2024-09-18 Stemcell Technologies Canada Inc. Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2024026491A2 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Enhanced antigen presenting cell formulations
WO2024026492A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Methods for treating cancer with enhanced antigen presenting cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1950106A (en) * 2003-12-24 2007-04-18 莱顿大学医学中心 Synthetic protein as tumor-specific vaccine
BRPI0812311A8 (en) * 2007-05-31 2019-02-05 Academisch Ziekenhuis Leiden use of a peptide derived from hpv protein e2, e6 and / or e7
WO2009039125A1 (en) * 2007-09-17 2009-03-26 The Schepens Eye Research Institute, Inc. Use of ocular neuropeptides as immune adjuvants
JP5797190B2 (en) * 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド Vaccine immunotherapy
PT2768942T (en) 2011-10-17 2020-01-21 Massachusetts Inst Technology Intracellular delivery
AU2015338893A1 (en) * 2014-10-31 2017-05-04 Massachusetts Institute Of Technology Delivery of biomolecules to immune cells
EP3344747B1 (en) 2015-09-04 2022-11-09 SQZ Biotechnologies Company Intracellular delivery of biomolecules mediated by a surface with pores
CN116218916A (en) * 2016-01-12 2023-06-06 Sqz生物技术公司 Intracellular delivery of complexes

Also Published As

Publication number Publication date
KR20200130835A (en) 2020-11-20
RU2020132504A3 (en) 2022-04-13
RU2020132504A (en) 2022-04-13
PH12020551436A1 (en) 2021-09-06
WO2019178006A2 (en) 2019-09-19
JP2021517813A (en) 2021-07-29
CR20200460A (en) 2020-11-23
AU2019234550A1 (en) 2020-10-01
EP3765068A2 (en) 2021-01-20
CN112135627A (en) 2020-12-25
IL277188A (en) 2020-10-29
WO2019178006A3 (en) 2019-11-07
CA3093828A1 (en) 2019-09-19
BR112020018612A2 (en) 2020-12-29
CO2020012584A2 (en) 2020-11-20
TW202003019A (en) 2020-01-16
MX2020009439A (en) 2021-01-08
MA52010A (en) 2021-01-20

Similar Documents

Publication Publication Date Title
IL277188A (en) Intracellular delivery of biomolecules to modify immune response
IL262677A (en) Intracellular delivery of biomolecules to induce tolerance
IL262676A (en) Intracellular delivery of biomolecules to induce tolerance
IL285809A (en) Delivery of biomolecules to pbmcs to modify an immune response
IL261188A (en) Antibodies to tigit
IL252005B (en) Delivery of biomolecules to immune cells
IL269499A (en) Stable antibody formulation
IL268881A (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
PL3344747T3 (en) Intracellular delivery of biomolecules mediated by a surface with pores
SG11201608207XA (en) Immune balance regulator
IL268731A (en) New uses of anti-sirpg antibodies
HK1257455A1 (en) Tgfbeta 2 antibodies
HK1256033A1 (en) Use of peptides to stimulate the immune system
DK3380120T3 (en) IMMUNE STIMULATING COMPOSITIONS
DK3191515T3 (en) LIGANDS THAT INCREASE THE BIOACTIVITY OF GONADOTROPINES
IL272933A (en) Preparation of solid dosage forms comprising antibodies by solution/ suspension layering
GB201609742D0 (en) Improvements relating to antibodies
IL269169A (en) Novel dosage form
SG11202001863PA (en) MODULATORS OF ENaC EXPRESSION
HUE059558T2 (en) Stabilized preparation of interferon beta variant
IL272015A (en) Antibodies to MADCAM
SG10201700022QA (en) Intradermal Administration Of Immunoglobulin G Preparation
ZA202100026B (en) Complex for enhancing immune response
RS20170960A1 (en) Preparation of products with stable parthenolde contentent
GB201715608D0 (en) Provision of virtual reality objects